Share This Article:

A Comparative Study on the Efficacy of Some Artemisinin Combination Therapies on Plasmodium berghei in Swiss Albino Mice

Full-Text HTML XML Download Download as PDF (Size:277KB) PP. 109-112
DOI: 10.4236/pp.2012.31016    5,517 Downloads   9,612 Views   Citations

ABSTRACT

This study evaluated and compared the efficacy of five brands of Artemisinin Combination Therapies (ACTs); Dihydroartemisinin plus Piperaquine, Artesunate plus Amodiaquine, Artesunate plus Sulphadoxine/Pyrimethamine, Artemether plus lumefantrine and Artesunate plus mefloquine combinations in vivo in P.berghei infected swiss albino mice. The experimental animals were pre-screened to rule out infection. All drugs were administered as clinical doses for the curative test and the Mean Percentage Parasitemia level assessed daily for seven days and on day 60. The results showed that all the drugs were effective with artesunate plus amodiaquine combination being the most efficacious followed by dihydroartemisinin plus piperaquine and artesunate plus sulphadoxine plus pyrimethamine combinations followed by artesunate plus mefloquine combination and artemether plus lumefantrine combination which was the least efficacious. Results on day 60 showed increasing parasitemia levels in mice which received Artemether plus lumefantrine and Artesunate plus mefloquine combinations which is indicative of recrudescence. The results of this study showed that the ACT’s used in the experiment were all efficacious. The possible development of resistance to some of the drugs was shown by the increasing parasitemia levels following treatment with artesunate plus lumefantrine and artesunate plus mefloquine combinations on day 60.

Cite this paper

U. Georgewill and O. Ebong, "A Comparative Study on the Efficacy of Some Artemisinin Combination Therapies on Plasmodium berghei in Swiss Albino Mice," Pharmacology & Pharmacy, Vol. 3 No. 1, 2012, pp. 109-112. doi: 10.4236/pp.2012.31016.

References

[1] J. W. Nicholas and J. G. Breman, “Malaria and Babeiosis; Diseases Caused by Red Blood Cell Parasites in Harrisons Principle of Medicine,” McGraw Hill, New York, 2005, p. 1218.
[2] N. Odebode and H. Shobiye, “Malaria Epidemics Loom as Parasites Develops Resistance to New Drug,” An Article in the Punch Newspapers Dated 12 July 2010. http://www.punch ng.com
[3] R. Ramachandra, “Resistance to Antimalarial Drugs Frontline,” Health (Indians National Magazine), 2004, pp. 34-37.
[4] S. Ehrhardt and C. G. Meyer, “Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria,” Therapeutics and Clinical Risk Management, Vol. 5, 2009, pp. 805-815. doi:10.2147/TCRM.S5375
[5] WHO Report, “Roll Back Malaria Partnership; Facts on ACTs (Artemisinin Based Combination Therapies,” January 2006 Update. http://www.rollbackmalaria.org
[6] Afrique en ligne, “Malaria Drug Resistance Warning Puts African Health Researchers on Edge,” Africa News, 2010. http://www.afriquejet.com
[7] U. Rane and P. Sehdeu, “Malaria Drug Development,” 1993. http://www.aaas.org/international/Africa/malaria/rane.html
[8] E. A. Ashley, K. Stepniewska and N. Lindeg?rdh, “Pharmacokinetic Study of Artemether-Lumefantrine Given Once Daily for the Treatment of Uncomplicated Multidrugresistant Falciparum Malaria,” Tropical Medicine and International Health, Vol. 12, No. 2, 2007, pp. 201-208. doi:10.1111/j.1365-3156.2006.01785.x
[9] B. S. Kakkilaya, “Combinatios of Antimalarial Drugs,” Dr B.S. Kakkilaya’s Malaria Website, 2009.
[10] WHO Report, “World Malaria Report,” 2008. http://www.who.int/malaria/wmr
[11] H. Myint, E. Ashley, N. Day, F. Nosten and N. White, “Efficacy and Safety of Dihydroartemisinin-Piperaquine,” Tropical Medicine and Hygiene, Vol. 101, No. 9, 2007, pp. 858-866. doi:10.1016/j.trstmh.2007.05.018
[12] M. R. Kamya, A. Yeka, H. Bukirwa, M. Lugemwa and J. B. Rwakimari, “Artemether-Lumefantrine versus Dihydrortemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial,” PLoS Clinical Trials, Vol. 2, No. 5, 2007, p. e20.
[13] M. Wilmer, Y. Laura, H. Ygor, A. Palacios, F. Eduardo, C. Cabezas, N. Arrospide, S. Guttierez and K. Trenton, “Efficacy and Tolerability of Artesunate plus Sulfadoxine-Pyrimethamine and Sulfadoxine Pyrimethamine Alone for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Peru,” American Journal of Tropical Medicine and Hygiene, Vol. 72, No. 5, 2005, pp. 568-572.
[14] M. Meremikwu, A. Alaribe, R. Ejemot, A. Oyo-ita, J. Ekenjoku C. Nwachukwu, D. Ordu and E. Ezedinachi, “Artemether/Lumefantrine versus Artesunate plus Amodiaquine for Treating Uncomplicated Childhood Malaria in Nigeria: Randomized Controlled Trial,” Malaria Jour- nal, Vol. 5, No. 43, 2006, PMC Free Article. doi:10.1186/1475-2875-5-43
[15] P. Olumese, “Antimalarial Combination Therapy,” Capa- city Development and Technical Support, Roll Back Malaria, 2009. http://www.apps.who.inf/malaria

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.